Opinion|Videos|July 23, 2024
Private Label Biosimilars
The expert panel discusses the greater potential for private label biosimilars.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- Some healthcare companies are investigating the potential for private label biosimilars, including products like adalimumab. What is the value of offering a private label biosimilar to patients? What are some of the challenges that may arise?
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
Walcker Named President of Cardinal’s The Specialty Alliance, With Strengths in GI, Urology
2
Ontada Analysis Finds GLP-1 RA Use Linked to Improved Survival in Patients With Cancer
3
Venetoclax-Obinutuzumab Tops Acalabrutinib in First-Line CLL
4
Gene Therapy Reduces LV Mass in Friedreich Ataxia Cardiomyopathy
5